Intranuclear protein transduction through a nucleoside salvage pathway

A method of delivering a conjugate to a target cell expressing a nucleoside transport pathway comprising,

• contacting the target cell expressing the nucleoside transport pathway with a conjugate comprising,
• a substrate that is capable of being transported by the nucleoside transport pathway, with the proviso that when the substrate is an antibody, it is not the monoclonal antibody 3E10 or a fragment thereof, and
• an active agent linked to the substrate,
• wherein the conjugate is transported by the nucleoside transport pathway, thereby transporting the conjugate into the target cell.

A method of treating a skeletal muscle disorder comprising,

• administering to a patient having a skeletal muscle disorder a conjugate comprising:
• a substrate that is capable of being transported by an equilibrative nucleoside transporter, and
• an active agent for treating the skeletal muscle disorder, wherein the active agent is linked to the substrate, and further wherein the conjugate is transported by the equilibrative nucleoside transporter,
• whereby the conjugate is transported into skeletal muscle cells, thereby delivering the active agent.

A method of treating a genetic disorder comprising,

• administering to a patient having a genetic disorder a conjugate comprising:
• a substrate that is capable of being transported by an equilibrative nucleoside transporter, and
• an active agent for treating the genetic disorder, wherein the active agent is linked to the substrate, and further wherein the conjugate is transported by the equilibrative nucleoside transporter,
• whereby the conjugate is transported into cells, thereby delivering the active agent.

A method of treating a cancer comprising,

• administering to a patient having cancer a conjugate comprising:
• a substrate that is capable of being transported by an equilibrative nucleoside transporter, and
• an active agent for treating cancer, wherein the active agent is linked to the substrate, and further wherein the conjugate is transported by the equilibrative nucleoside transporter,
• whereby the conjugate is transported into cancerous cells, thereby delivering the active agent.